Zeng G - Search Results

1

Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study.

Song R, Zeng G, Yu J, Meng X, Chen X, Li J, Xie X, Lian X, Zhang Z, Cao Y, Yin W, Jin R. Song R, et al. Among authors: zeng g. Emerg Microbes Infect. 2023 Dec;12(1):2212806. doi: 10.1080/22221751.2023.2212806. Emerg Microbes Infect. 2023. PMID: 37157134 Free PMC article. Clinical Trial.

2

A Randomized Controlled Trial to Evaluate a Potential Hepatitis B Booster Vaccination Strategy Using Combined Hepatitis A and B Vaccine.

Li F, Hu Y, Zhou Y, Chen L, Xia W, Song Y, Tan Z, Gao L, Yang Z, Zeng G, Han X, Li J, Li J. Li F, et al. Among authors: zeng g. Pediatr Infect Dis J. 2017 May;36(5):e157-e161. doi: 10.1097/INF.0000000000001535. Pediatr Infect Dis J. 2017. PMID: 28060048 Clinical Trial.

3

Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation.

Hu Y, Zeng G, Chu K, Zhang J, Han W, Zhang Y, Li J, Zhu F. Hu Y, et al. Among authors: zeng g. Hum Vaccin Immunother. 2018 Jun 3;14(6):1517-1523. doi: 10.1080/21645515.2018.1442997. Epub 2018 Apr 11. Hum Vaccin Immunother. 2018. PMID: 29482422 Free PMC article. Clinical Trial.

4

Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial.

Hu Y, Wang J, Zeng G, Chu K, Jiang D, Zhu F, Ying Z, Chen L, Li C, Zhu F, Yin W. Hu Y, et al. Among authors: zeng g. J Infect Dis. 2019 Oct 8;220(10):1551-1557. doi: 10.1093/infdis/jiy736. J Infect Dis. 2019. PMID: 30958543 Clinical Trial.

5

Interchangeability of two Enterovirus 71 inactivated vaccines in Chinese children: A phase IV, open-label, and randomized controlled trial.

Xu Q, Cao Q, Yang W, Liu X, Liu H, Tian X, Li J, Fang X, Jia N, Zeng G, Xu A. Xu Q, et al. Among authors: zeng g. Vaccine. 2020 Mar 10;38(12):2671-2677. doi: 10.1016/j.vaccine.2020.02.013. Epub 2020 Feb 14. Vaccine. 2020. PMID: 32067817 Clinical Trial.

6

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. Zhang Y, et al. Among authors: zeng g. Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17. Lancet Infect Dis. 2021. PMID: 33217362 Free PMC article. Clinical Trial.

7

Immunogenicity and Safety of Inactivated Enterovirus 71 Vaccine in Children Aged 36-71 Months: A Double-Blind, Randomized, Controlled, Non-inferiority Phase III Trial.

Zhang L, Gao F, Zeng G, Yang H, Zhu T, Yang S, Meng X, Mao Q, Liu X. Zhang L, et al. Among authors: zeng g. J Pediatric Infect Dis Soc. 2021 Apr 30;10(4):440-447. doi: 10.1093/jpids/piaa129. J Pediatric Infect Dis Soc. 2021. PMID: 33269798 Clinical Trial.

8

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.

Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, Wu Z, Jiang D, Deng X, Chu K, Zheng W, Wang L, Lu W, Han B, Zhao Y, Zhu F, Yu H, Yin W. Zeng G, et al. Lancet Infect Dis. 2022 Apr;22(4):483-495. doi: 10.1016/S1473-3099(21)00681-2. Epub 2021 Dec 8. Lancet Infect Dis. 2022. PMID: 34890537 Free PMC article. Clinical Trial.

9

Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study - Hohhot City, Inner Mongolia Autonomous Region, China, 2022.

Si S, Jin C, Li J, Cao Y, Kan B, Xue F, Xie XS, Fang L, Zeng G, Zhang S, Hu Y, Dong X. Si S, et al. Among authors: zeng g. China CDC Wkly. 2023 Mar 10;5(10):218-222. doi: 10.46234/ccdcw2023.040. China CDC Wkly. 2023. PMID: 37006441 Free PMC article.

10

Immunogenicity and Safety of Homologous Booster Doses of CoronaVac COVID-19 Vaccine in Elderly Individuals Aged 60 Years and Older: A Dosing Interval Study - Yunnan Province, China, 2021-2022.

Yang H, Meng X, Zhuang T, Wang C, Yang Z, Zhu T, Li M, Zheng Y, Wu Q, Hu Y, Yu H, Liu X, Zeng G. Yang H, et al. Among authors: zeng g. China CDC Wkly. 2023 Feb 10;5(6):125-130. doi: 10.46234/ccdcw2023.023. China CDC Wkly. 2023. PMID: 37008828 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,767 results

Search Page